China’s Global Push
Clinical evidence points to immune system ‘reset’ and durable remission. Investors have taken note and the deals have followed.
Launching In Vivo’s oncology therapeutic review series, this first instalment provides a data-led primer on the global cancer landscape. Future instalments will explore market dynamics, pipeline evolution and the innovations set to define oncology therapeutics through 2032.
Seed investors are enthusiastic about AI in drug discovery but skeptical of the valuations it is used to justify. At a recent panel, they drew a sharp line between real capability and an “AI veneer.”
Merck's post-Keytruda oncology strategy rests on three pillars – immune deepening, tissue targeting and tumor-intrinsic mechanisms – anchored by patient selection, AI-accelerated discovery and a KRAS bet that could define its next era.
Industry leaders share how Britain can strengthen its biotech ecosystem, from capital and regulation to talent and ambition, and what the sector could look like by 2030.
In this two-part series, In Vivo examines who is building the autonomous lab, what architectural and business model choices they are making, and what the implications are for drug discovery organizations, external R&D partnerships and the workforce that will be asked to operate these systems.
As India implements minimum import prices for certain antibiotics and key starting materials, Sandoz's Simon Goeller speaks to Generics Bulletin about the potential for Chinese suppliers to dominate the world market and weaponize supply.
A decade ago, China was buying Western drugs. Now it is selling them. Executives who ignore the shift do so at their peril.
Recent BCG reports and interviews reveal an industry under pressure and racing to adapt through AI, new deal structures and direct-to-patient models.
Nine $1bn+ alliances were penned in January, and three exceeded $2bn. In the top alliance by deal value, RemeGen granted AbbVie exclusive global rights (excluding Greater China) to develop, manufacture, and commercialize RC148 for non-small cell lung cancer and other solid tumors.
Boehringer Ingelheim is restructuring its therapeutic operations to push decision-making closer to brand teams while keeping R&D spending around 25% of revenues.
During Q4, biopharma merger and acquisition deal value reached $94.8bn and drew in $74.7bn in potential deal value from alliances. Device company M&A values reached $3.5bn, while in vitro diagnostics and research tools players’ M&A activity totaled $39.8m.
As the race to transform Duchenne muscular dystrophy care accelerates, Santhera Pharmaceuticals’ chief medical officer Shabir Hasham discusses how treatment is evolving, why combination therapies may define the next era and what it will take to improve life for patients and families living with DMD.
During Q4, biopharmas brought in an aggregate $30bn in financing and device company fundraising totaled $9.7bn; while in vitro diagnostic firms and research tools players raised $1.5bn.
Cell and gene therapy is shifting into a new phase, as maturing commercial launches, rising big pharma participation and regulatory momentum replace hype and skepticism.
The medtech industry has been disrupted by tariffs and China’s volume-based procurement policies. While India is expected to emerge as a key long-term growth market, near-term upside may come from a potential rebound in EU attractiveness following the MDR reform proposals in December 2025.
The pharma titan candidly speaks about the M&A landscape, high R&D costs and the potential of AI as the industry gets set to navigate a host of existing and new challenges.
It’s time for In Vivo's 18th annual Deals of the Year contest. We've chosen 15 nominees across three categories – Top M&A, Top Alliance, and Top Financing – and now it’s your turn to pick the winners.